AB1460 prohibits prescription drug manufacturers from imposing conditions or restrictions that interfere with a qualifying nonhospital 340B community clinic’s ability to use specified pharmacies — including contract pharmacies — to purchase or dispense drugs eligible for federal 340B discounts. The bill enumerates examples of prohibited "discriminatory practices," preserves federal 340B audit rights, and lets manufacturers request certain deidentified claim identifiers on an annual basis while forbidding withholding discounts during reconciliation.
This matters because it focuses state law on protecting the operational relationship between safety-net clinics and the pharmacies that serve their patients. The measure shifts compliance responsibilities onto clinics (annual audits, reporting how 340B savings are used, and yearly recertification with HRSA) while constraining manufacturers’ leverage over which pharmacies clinics can use — with implications for program integrity, privacy, and implementation costs for covered entities and contract pharmacies.
At a Glance
What It Does
The bill bars manufacturers from imposing restrictions that would limit a qualifying nonhospital 340B community clinic’s use of specified pharmacies (including contract pharmacies) and lists illustrative prohibited practices. It requires clinics to perform annual independent audits of contract pharmacies, report how 340B savings are used to HRSA, and recertify covered-entity status annually. Manufacturers may request deidentified invoice and claim identifiers once per year but cannot withhold 340B discounts while reconciling data.
Who It Affects
Qualifying nonhospital 340B community clinics (as defined by state licensure and federal 340B covered-entity status), contract pharmacies that dispense medications to eligible patients, and prescription drug manufacturers selling covered outpatient drugs. HRSA and independent audit firms also figure into the compliance chain.
Why It Matters
The bill narrows manufacturers’ leverage over pharmacy networks and reinforces clinic access to contract pharmacy networks — a core operational component of many safety-net providers. It also reallocates compliance tasks and costs to clinics while creating a limited, privacy‑constrained pathway for manufacturers to investigate duplicate discounts and diversion.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB1460 sets a clear state-level rule: drug manufacturers may not adopt policies that impose extra conditions or otherwise interfere with a qualifying nonhospital 340B community clinic’s ability to buy or dispense drugs through a specified pharmacy, including contract pharmacies. The statute includes examples — such as requiring a clinic to use only one contract pharmacy, banning use of contract pharmacies where the clinic has an in‑house pharmacy, placing distance-based shipping limits, or narrowing which medicines are eligible for discounts — to make the scope of prohibited conduct concrete, though the list is illustrative rather than exhaustive.
The bill keeps federal 340B law in place and explicitly preserves the Secretary of Health and Human Services’ and manufacturers’ federally authorized audit rights over covered entities; California does not attempt to alter federal audit procedures. At the same time, AB1460 adds state-imposed compliance duties on qualifying nonhospital 340B community clinics: an annual independent audit of any contract pharmacies with corrective action as needed, an annual report to HRSA describing how 340B savings fund patient care, and annual recertification with HRSA.
These obligations formalize program-integrity steps at the clinic level and make program use more transparent to federal overseers.On information sharing, the bill strikes a compromise. Manufacturers may request the invoice number, unique identifier, and coding tied to a claim to investigate duplicate discounts, diversion, or eligibility, but that information must be deidentified consistent with HIPAA and other privacy laws, may be requested only once per year, and manufacturers may not withhold 340B discounts while they reconcile the data.
Operationally, that creates a limited, periodic channel for manufacturers to validate claims without creating a continuous leverage point to block discounts.Implementation will hinge on definitions and process. The bill defines qualifying nonhospital 340B community clinics by tying them to specific state licensing categories and the federal 340B covered-entity status.
It does not create a new enforcement agency or civil penalty regime in the text; enforcement would rely on existing state mechanisms unless regulations or later provisions specify otherwise. Practically, clinics will need to budget for independent audits and reporting, contract pharmacies must be prepared for more oversight, and manufacturers will need to adjust contract terms and their investigative workflows to comply with the statute’s restraints and privacy requirements.
The Five Things You Need to Know
The bill forbids manufacturers from imposing conditions that limit a qualifying nonhospital 340B community clinic’s use of a specified pharmacy, including prohibiting clinics from using contract pharmacies.
It requires qualifying nonhospital 340B community clinics to conduct annual independent audits of contract pharmacies, take corrective action for deficiencies, and recertify annual covered-entity status with HRSA.
Clinics must identify and report annually to HRSA how 340B savings are being used to support patient care.
Manufacturers may request deidentified invoice numbers, unique identifiers, and coding associated with claims once per year to investigate duplicate discounts or diversion, but must comply with HIPAA and state privacy laws.
The bill prohibits manufacturers from withholding 340B discounts while claims data are being reconciled following a data request.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Prohibition on discriminatory practices by manufacturers
This subsection is the operative ban: manufacturers may not impose additional conditions, prohibit, restrict, deny, or otherwise interfere with a qualifying nonhospital 340B community clinic’s purchase or delivery of 340B-eligible drugs when the clinic uses a specified pharmacy, including a contract pharmacy. For covered entities that rely on contract pharmacy networks to reach patients, this removes contractual and programmatic levers manufacturers have used to influence network composition.
Preservation of existing law and federal audit rights
Subdivision (b) states the bill does not alter existing state law. Subdivision (c) clarifies legislative intent that the statute should not change federal 340B requirements and explicitly preserves HRSA and manufacturer audit rights under Section 340B of the Public Health Service Act. Practically, California asserts state protections for clinic pharmacy choice without attempting to supersede federal audit authorities or federal program rules.
Annual clinic compliance duties: audits, reporting, recertification
This clause obligates qualifying nonhospital 340B community clinics to: (1) conduct annual independent audits of contract pharmacies and address deficiencies; (2) identify and report to HRSA how 340B savings are used to support patient care; and (3) recertify covered-entity status annually with HRSA. These are affirmative duties that shift program‑integrity work to clinics and create recurring administrative and financial responsibilities for covered entities.
Definition of discriminatory practices and qualifying clinics
Subdivision (e)(1) provides an illustrative, non‑exclusive list of what counts as discriminatory practices (e.g., limiting clinics to one contract pharmacy, distance-based shipment restrictions, or narrowing eligible medications). Subdivision (e)(2) ties the "qualifying nonhospital 340B community clinic" label to specific California licensure categories and to federal 340B covered-entity status, which determines who benefits from the prohibition and who must comply with the new clinic duties.
Manufacturer data requests limited and privacy‑constrained
Manufacturers may request invoice numbers, unique identifiers, and coding tied to claims for purposes such as identifying duplicate discounts or diversion, but claims must be deidentified and requests may occur only annually. The provision explicitly conditions requests on compliance with federal and state privacy laws (including HIPAA) and forbids withholding 340B discounts while reconciliation occurs. This creates a single, privacy-protected channel for investigation without allowing manufacturers to use ongoing data demands to block discounts.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Qualifying nonhospital 340B community clinics — The ban on manufacturer-imposed pharmacy restrictions preserves clinics’ operational ability to use contract pharmacies to reach patients, protecting access and revenue streams tied to 340B discounts.
- Patients served by safety-net clinics — By maintaining contract pharmacy access and prohibiting manufacturers from restricting pharmacies, patients are less likely to face disruptions in pharmacy choice or medication access.
- Contract pharmacies — The measure reduces the risk that manufacturers will force clinics to eliminate or limit contract pharmacy arrangements, protecting pharmacy revenue tied to dispensing for 340B-covered patients.
- Federal program oversight (HRSA) — The required clinic reporting on use of 340B savings and annual recertification creates more documentation for HRSA to monitor program use and target enforcement or guidance.
Who Bears the Cost
- Qualifying nonhospital 340B community clinics — Clinics must fund annual independent audits of contract pharmacies, prepare HRSA reports on savings use, and manage annual recertification, adding recurring administrative and financial burdens.
- Contract pharmacies — Increased auditing and oversight may require additional recordkeeping, compliance processes, and cooperation with independent auditors, raising operational costs.
- Prescription drug manufacturers — The statute removes certain contractual levers to shape pharmacy networks and restricts the timing and scope of claims-data requests, potentially increasing manufacturers’ transaction and investigative costs.
- State and federal agencies — HRSA and state health regulators may face higher administrative workloads processing clinic reports and overseeing compliance, without a dedicated funding stream in the statute.
Key Issues
The Core Tension
The central dilemma is balancing access and program integrity: protecting clinics and patients from manufacturer-imposed limits on contract pharmacies preserves access but constrains manufacturers’ tools to prevent diversion and duplicate discounts; simultaneously, imposing annual audit and reporting duties on clinics advances transparency but places recurring costs on safety-net providers that may erode the financial benefits the 340B program is meant to deliver.
AB1460 walks a narrow line between protecting clinic access to contract pharmacies and preserving federal program-integrity tools. Because the bill explicitly preserves federal audit rights, much of the hardest operational work still lives at the federal level; California’s new clinic duties create parallel state‑level expectations but do not establish a state enforcement regime with clear penalties or remedies in the text.
That gap leaves open questions about how disputes — for example, when a manufacturer alleges diversion and a clinic disputes the claim — will be resolved and which forum will adjudicate withheld-discount disputes if they arise despite the statutory prohibition.
The bill’s definitions and illustrative list of "discriminatory practices" give plaintiffs and regulators a roadmap, but terms such as "arbitrary distance limitations" and rules about shipping to patients introduce fact-intensive lines that courts or regulators will likely have to interpret. The once‑per‑year, deidentified data-sharing compromise reduces privacy risk but may slow detection of ongoing diversion or duplicate discounts; annual snapshots are less useful for spotting patterns that emerge between reporting periods.
Finally, shifting audit costs onto clinics may paradoxically shrink net benefits for smaller covered entities if the added compliance burden offsets 340B savings, creating a resource-allocation trade-off between program integrity and clinic viability.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.